03/25/2013
Because regulatory bodies require that manufacturers apply current good manufacturing practices (cGMP) quality control measures to ensure product safety, manufacturers must confirm that production processes are sufficiently controlled to prevent adulteration of the product and risk to consumers. In order to better help our customers meet these regulatory requirements, Charles River is pleased to now offer the Accugenix® AccuGENX-ST™.
03/20/2013
We are now the exclusive distributor of the TARGATT™ mouse. The TARGATT mouse is a transgenic mouse designed to produce animal models with investigator designed exogenous DNA sequences knocked-in to a specific site.
03/18/2013
Successful drug discovery relies on the selection of drug candidates with good in vivo pharmacokinetic (PK) properties as well as appropriate preclinical efficacy and safety profiles. In vivo PK profiling is often a bottleneck in the discovery process.
03/14/2013
Charles River was proud to support this meeting with roundtables, exhibitor sessions, poster presentations and a continuing education course. Below is a sampling of some of the posters we presented at SOT.
03/11/2013
Our new facility allows you to take advantage of increased capacity and harmonized procedures between our EU and US-based sites, as well as expanded support services to strengthen your viral clearance studies.
03/08/2013
Our new webinar series allows you to learn more about the three new reporter mouse models offered through our collaboration with Transgenic Operative Products (T.O.P.) srl.
02/28/2013
Charles River offers animal models with combined surgeries or services (e.g., feeding studies with tissue collection) to help meet the ever changing needs of our customers.
02/18/2013
We are employing various biological materials and biosimilars in both in vivo and CNS efficacy studies in order to create and validate study models of neurological and psychological diseases. These therapeutic interventions include administration of proteins, RNA and stem cells.
02/11/2013
As part of our ongoing development program in the areas of neurology and psychiatry, we are pleased to introduce an updated and fully validated preclinical in vivo model for the study of compounds and therapies aimed at combating the cognitive and negative symptoms of schizophrenia.
02/11/2013
Our recently expanded health surveillance portfolio now includes health surveillance assays for additional species to augment your colony quality control program.